Source link : https://www.newshealth.biz/health-news/tirzepatide-reduces-heart-failure-events-in-hfpef-with-obesity/
CHICAGO — A new study has shown for the first time that a drug therapy can reduce major heart failure clinical outcomes in patients with heart failure and a preserved ejection fraction (HFpEF) and obesity. The SUMMIT trial found that tirzepatide, a long-acting agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, reduced […]
Author : News Health
Publish date : 2024-11-16 18:50:32
Copyright for syndicated content belongs to the linked Source.